Liwei Zhao

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Topics

Endoplasmic Reticulum

Tyrosine Kinase

Top Venues

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Liwei Zhao, Peng Liu, Misha Mao, Shuai Zhang, Camille Bigenwald, Charles-Antoine Dutertre, Christian H K Lehmann, Hui Pan, Nicolas Paulhan, Lukas Amon, Aitziber Buque, Takahiro Yamazaki, Lorenzo Galluzzi, Benoit Kloeckner, Aymeric Silvin, Yuhong Pan, Hui Chen, Ai-Ling Tian, Pierre Ly, Diana Dudziak, Laurence Zitvogel, Oliver Kepp, Guido Kroemer
BCL2 inhibition reveals a dendritic cell-specific immune checkpoint that controls tumor immunosurveillance. Cancer discovery (2023)
Peng Liu, Liwei Zhao, Gladys Ferrere, Carolina Alves-Costa-Silva, Pierre Ly, Qi Wu, Ai-Ling Tian, Lisa Derosa, Laurence Zitvogel, Oliver Kepp, Guido Kroemer
Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. Oncoimmunology 9 (1) (2020)
Oliver Kepp, Peng Liu, Liwei Zhao, Isabelle Plo, Guido Kroemer
Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis. Oncoimmunology 9 (1) (2020)
Peng Liu, Liwei Zhao, Oliver Kepp, Guido Kroemer
Crizotinib - a tyrosine kinase inhibitor that stimulates immunogenic cell death. Oncoimmunology 8 (7) (2019)
Oliver Kepp, Allan Sauvat, Marion Leduc, Sabrina Forveille, Peng Liu, Liwei Zhao, Lucillia Bezu, Wei Xie, Laurence Zitvogel, Guido Kroemer
A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers. Oncoimmunology 8 (8) (2019)
Peng Liu, Liwei Zhao, Guido Kroemer, Oliver Kepp
Secreted calreticulin mutants subvert anticancer immunosurveillance. Oncoimmunology 9 (1) (2019)